Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01944462 · ClinicalTrials.gov registry record · Phase 4
Impact and Cost of a Pharmacist Pneumococcal Vaccination Program With PNEUMOVAX® 23 at an Urban Senior Center
A Phase 4 study, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- Phase 4
- Development phase
- 203
- Enrollment target
NCT01944462: Completed Phase 4 study, sponsored by Thomas Jefferson University.
NCT01944462 is a Phase 4 study that has completed, run by Thomas Jefferson University. The registered enrollment target is 203 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01944462, a Phase 4 study, has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 203 participants
- Enrollment target
Study Summary
The overall goals of this program are to measure the impact of a pharmacist pneumococcal vaccine education program (PPVP) using a senior center model of care and provide the pneumococcal vaccine to eligible participants. Hypotheses 1. PPVP will result in improved knowledge and awareness in older minorities in the senior center setting (primary hypothesis); 2. Participants who are vaccinated through the project will experienced increased trust in receiving vaccines from a pharmacist; 3. Participants will be satisfied with and trust the PV information provided by pharmacists in the PPVP; 4. PPVP is an efficient approach to educating patients in the senior center based on its costs; 5. Participating pharmacists will be activated to implement PPVP learnings in their practice.
Primary Outcome
Change in knowledge and awareness of pneumococcal disease over time were assessed for the following domains: susceptibility to infection, symptoms of disease, severity of illness, and vaccination with an emphasis on vaccine efficacy, safety, and eligibility. Assessments at baseline, post-test (immediately following intervention), and 3 months using the Pneumonia Knowledge Questionnaire, an instrument developed by investigators to assess participants' knowledge and awareness in the domains of int
Interventions
- BEHAVIORAL Pharmacist Pneumococcal Vaccine Program (PPVP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-11 |
| Phase | Phase 4 |
What the finished NCT01944462 record still lists
NCT01944462 is an interventional study that assigns participants to a tested intervention. The registered 203 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (61% lower).
The record links to 0 conditions, and to 1 intervention - of which Pharmacist Pneumococcal Vaccine Program (PPVP) is the first listed.
NCT01944462 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01944462 about?
NCT01944462 is a clinical study titled "Impact and Cost of a Pharmacist Pneumococcal Vaccination Program With PNEUMOVAX® 23 at an Urban Senior Center". The overall goals of this program are to measure the impact of a pharmacist pneumococcal vaccine education program (PPVP) using a senior center model of care and provide the pneumococcal vaccine to eligible participants. Hypotheses 1. PPVP will result in improved knowledge and awareness in older m...
What is the current status of trial NCT01944462?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 203 participants. The study started on 2014-01. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01944462?
The interventions under investigation include: Pharmacist Pneumococcal Vaccine Program (PPVP) (BEHAVIORAL).
Who is sponsoring clinical trial NCT01944462?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01944462's enrollment target sits among peer trials
203 403rd of 2000 higher than 1,597 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05652686 · 203 participants · Phase 1
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- NCT06063122 · 203 participants · NA
Development of a Therapeutic Device to Improve Speech Sound Differentiation in Preterm Infants
- NCT07031245 · 203 participants · NA
Evidence-Based Quality Improvement to Reduce VA Primary Care Burnout
- NCT03481010 · 204 participants · NA
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia